Substance / Medication

Isradipine

Overview

Active Ingredient
isradipine
RxNorm CUI
33910
Labeler: AvKAREUpdated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Applications of isradipine in human addiction studies: A systematic literature review.
Natal Samantha, Young Cara C, Kaur Karamveer et al. · Exp Clin Psychopharmacol · 2023
PMID: 36595455Meta-AnalysisFull text (PMC)
Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial.
Young Cara C, Papini Santiago, Minami Haruka et al. · Neuropsychopharmacology · 2024
PMID: 38789642RCTFull text (PMC)
Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals.
Johnson Bankole A, Roache John D, Ait-Daoud Nassima et al. · Int J Neuropsychopharmacol · 2005
PMID: 15916717RCT
Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
Venuto Charles S, Yang Luoying, Javidnia Monica et al. · Ann Clin Transl Neurol · 2021
PMID: 33460320TrialFull text (PMC)
Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
Simuni Tanya, Borushko Emily, Avram Michael J et al. · Mov Disord · 2010
PMID: 20818667Trial
Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals.
Johnson Bankole A, Javors Martin A, Lam Yui-Wing Francis et al. · Prog Neuropsychopharmacol Biol Psychiatry · 2005
PMID: 15610940Trial
Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition.
Johnson Bankole A, Roache John D, Ait-Daoud Nassima et al. · Psychopharmacology (Berl) · 2005
PMID: 15452681Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Isradipine (substance)
SNOMED CT
386862002
UMLS CUI
C0071304
RxNorm CUI
33910
Labeler
AvKARE

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.